Glucagon
Also known as: Baqsimi, Glucagen, Gvoke, Gvoke Hypopen 1-Pk, Gvoke Hypopen 2-Pk, Gvoke Hypopen 2pk, Gvoke Pfs 1-Pk, Gvoke Pfs 2-Pk.
Wholesale (NADAC) cost for every strength and dosage form — the price pharmacies pay, published weekly by CMS. Not your out-of-pocket price.
Wholesale (NADAC) prices — every strength & form
| Strength | Form | NADAC / unit | Package | Class |
|---|---|---|---|---|
| 0.5 MG/0.1 ML | Pen | $3,200.63 / mL† | — | Brand |
| 1 MG | Kit | $165.09 / unit† | — | Generic |
| 1 MG | Vial | $165.09 / unit† | — | Generic |
| 1 MG/0.2 ML | Kit | $1,598.10 / mL† | — | Brand |
| 1 MG/0.2 ML | Vial | $1,598.10 / mL† | — | Brand |
| 1 MG/0.2 ML | Pen | $1,600.62 / mL† | — | Brand |
| 1 MG/0.2 ML | Syringe | $1,604.12 / mL† | — | Brand |
| 3 MG | Spray | $293.39 / unit | — | Brand |
| 3 MG | Packet | $293.61 / unit | — | Brand |
Wholesale (NADAC) — the price pharmacies pay, not your out-of-pocket price. Brand list prices fall after confidential rebates. † Package size not curated yet — priced per single unit/mL, not per full pen, inhaler, or vial.
NADAC week of 2026-07-01 · updated weekly · source CMS
Medicaid & Medicare spending · 2024
In 2024, Medicaid paid $96,395,036 gross for Glucagon across 203,144 prescriptions (measured, national).
Medicare Part D EST spent an estimated ~$112,779,099 gross (retail pharmacy only; excludes Part B).
Gross program spending, before rebates — not what patients pay out of pocket. Brand net cost is materially lower after confidential rebates; generics are close to net.
Source: Medicaid SDUD 2024 · Medicare Part D 2024 · CMS